How does a Human Papillomavirus (HPV) infection connect to a sinus nasal cancerous growth?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HPV and Sinonasal Cancerous Growths: The Connection

HPV infection can directly contribute to sinonasal cancerous growths through its oncogenic properties, with up to 21-33% of sinonasal carcinomas testing positive for high-risk HPV strains, particularly HPV-16. 1, 2

Pathophysiological Connection Between HPV and Sinonasal Cancer

HPV Types and Prevalence

  • High-risk HPV types (particularly type 16,18,31, and 33) are the predominant strains detected in sinonasal cancers 1
  • Approximately 21% of sinonasal carcinomas are positive for high-risk HPV DNA 1
  • HPV-related sinonasal carcinomas represent a distinct entity with specific characteristics

Mechanism of Carcinogenesis

  • HPV infects the epithelial cells of the sinonasal tract
  • Viral oncoproteins (E6 and E7) disrupt normal cell cycle regulation
  • p16 overexpression is a reliable surrogate marker for HPV infection in these tumors, with 97% of HPV-positive sinonasal tumors exhibiting high p16 expression 1

Clinical and Histopathological Features

Histological Spectrum

  • Most common type: Nonkeratinizing or partially keratinizing squamous cell carcinoma 1
  • Other variants include:
    • Papillary squamous cell carcinoma
    • Adenosquamous carcinoma
    • Basaloid squamous cell carcinoma
    • HPV-related multiphenotypic sinonasal carcinoma (HMSC) 3, 4

Diagnostic Approach

  • Definitive diagnosis requires endoscopic-guided biopsy of the sinonasal tumor 5
  • HPV testing should be performed on all sinonasal carcinomas using:
    • p16 immunohistochemistry as an initial screening test
    • DNA in situ hybridization or PCR for confirmation of HPV presence 5
  • Material should be collected in formalin or suitable fixative to allow for HPV testing 5

Clinical Significance and Prognosis

Prognostic Implications

  • HPV-positive sinonasal carcinomas show a trend toward improved survival compared to HPV-negative tumors (hazard ratio=0.58) 1
  • HPV-related multiphenotypic sinonasal carcinoma (HMSC) demonstrates an indolent clinical course despite aggressive radiological features 3, 4
  • Some HPV-related sinonasal tumors may recur very late (even after decades) 4

Treatment Considerations

  • Endoscopic surgical resection is often achievable despite complex radiological appearance 3
  • Adjuvant radiation therapy is typically recommended following surgical resection 3
  • HPV status should be determined as it may influence treatment decisions and prognostic discussions 6

Differential Diagnosis

Other Viral Associations

  • While HPV is associated with sinonasal cancers, Epstein-Barr virus (EBV) is more commonly associated with nasopharyngeal carcinoma 5
  • For neck metastases of unknown origin, both HPV and EBV status should be determined 5
  • EBV testing is performed through Epstein-Barr-encoded RNA (EBER) using in situ hybridization 5

Pitfalls and Caveats

  • Initial misdiagnosis is common due to morphologic overlap with other sinonasal tumors (particularly adenoid cystic carcinoma) 4
  • HPV-related sinonasal tumors may have a heterogeneous etiology, with both HPV-related and non-related factors contributing 2
  • Technical factors in testing may lead to discrepancies in HPV detection rates across studies 2
  • The incidence of HPV-positive sinonasal cancers appears to be increasing, highlighting the importance of routine HPV testing 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.